vs
CytomX Therapeutics, Inc.（CTMX）与FiscalNote Holdings, Inc.（NOTE）财务数据对比。点击上方公司名可切换其他公司
FiscalNote Holdings, Inc.的季度营收约是CytomX Therapeutics, Inc.的1.2倍（$22.2M vs $18.7M），FiscalNote Holdings, Inc.同比增速更快（-24.7% vs -25.7%），FiscalNote Holdings, Inc.自由现金流更多（$-1.9M vs $-15.8M），过去两年CytomX Therapeutics, Inc.的营收复合增速更高（-15.9% vs -16.8%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
FiscalNote Holdings, Inc.（常称FiscalNote）是一家上市的软件数据与传媒企业，总部位于美国华盛顿特区，2013年由三位创始人创立。核心业务为通过政府关系管理服务FiscalNote GRM提供软件工具、平台、数据服务与资讯，同时依托人工智能平台分析美国待审议法案相关内容。
CTMX vs NOTE — 直观对比
营收规模更大
NOTE
是对方的1.2倍
$18.7M
营收增速更快
NOTE
高出1.1%
-25.7%
自由现金流更多
NOTE
多$13.9M
$-15.8M
两年增速更快
CTMX
近两年复合增速
-16.8%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $22.2M |
| 净利润 | $-154.0K | — |
| 毛利率 | — | — |
| 营业利润率 | -6.9% | -83.7% |
| 净利率 | -0.8% | — |
| 营收同比 | -25.7% | -24.7% |
| 净利润同比 | 97.6% | — |
| 每股收益（稀释后） | — | $-2.81 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMXNOTE
| Q4 25 | — | $22.2M | ||
| Q3 25 | — | $22.4M | ||
| Q2 25 | $18.7M | $23.3M | ||
| Q1 25 | $50.9M | $27.5M | ||
| Q4 24 | $38.1M | $29.5M | ||
| Q3 24 | $33.4M | $29.4M | ||
| Q2 24 | $25.1M | $29.2M | ||
| Q1 24 | $41.5M | $32.1M |
净利润CTMXNOTE
| Q4 25 | — | — | ||
| Q3 25 | — | $-24.9M | ||
| Q2 25 | $-154.0K | $-13.3M | ||
| Q1 25 | $23.5M | $-4.3M | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $-14.9M | ||
| Q2 24 | $-6.5M | $-12.8M | ||
| Q1 24 | $13.8M | $50.6M |
营业利润率CTMXNOTE
| Q4 25 | — | -83.7% | ||
| Q3 25 | — | -43.4% | ||
| Q2 25 | -6.9% | -31.9% | ||
| Q1 25 | 44.4% | -50.0% | ||
| Q4 24 | 46.4% | -19.4% | ||
| Q3 24 | 12.3% | -23.1% | ||
| Q2 24 | -33.7% | -27.2% | ||
| Q1 24 | 28.1% | -35.6% |
净利率CTMXNOTE
| Q4 25 | — | — | ||
| Q3 25 | — | -110.8% | ||
| Q2 25 | -0.8% | -57.0% | ||
| Q1 25 | 46.2% | -15.4% | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | -50.7% | ||
| Q2 24 | -26.0% | -43.6% | ||
| Q1 24 | 33.3% | 157.6% |
每股收益（稀释后）CTMXNOTE
| Q4 25 | — | $-2.81 | ||
| Q3 25 | — | $-1.73 | ||
| Q2 25 | — | $-0.08 | ||
| Q1 25 | — | $-0.03 | ||
| Q4 24 | — | $1.88 | ||
| Q3 24 | — | $-1.33 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | — | $0.37 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | $26.3M |
| 总债务越低越好 | — | $128.4M |
| 股东权益账面价值 | $119.9M | $62.0M |
| 总资产 | $175.1M | $255.1M |
| 负债/权益比越低杠杆越低 | — | 2.07× |
8季度趋势，按日历期对齐
现金及短期投资CTMXNOTE
| Q4 25 | — | $26.3M | ||
| Q3 25 | — | $31.2M | ||
| Q2 25 | $49.0M | $38.5M | ||
| Q1 25 | $47.6M | $46.3M | ||
| Q4 24 | $38.1M | $34.6M | ||
| Q3 24 | $40.6M | $32.7M | ||
| Q2 24 | $43.2M | $37.7M | ||
| Q1 24 | $36.2M | $43.6M |
总债务CTMXNOTE
| Q4 25 | — | $128.4M | ||
| Q3 25 | — | $131.5M | ||
| Q2 25 | — | $116.7M | ||
| Q1 25 | — | $118.0M | ||
| Q4 24 | — | $147.1M | ||
| Q3 24 | — | $152.2M | ||
| Q2 24 | — | $145.9M | ||
| Q1 24 | — | $153.0M |
股东权益CTMXNOTE
| Q4 25 | — | $62.0M | ||
| Q3 25 | — | $75.5M | ||
| Q2 25 | $119.9M | $95.1M | ||
| Q1 25 | $25.0M | $98.7M | ||
| Q4 24 | $-456.0K | $97.8M | ||
| Q3 24 | $-23.5M | $98.5M | ||
| Q2 24 | $-31.2M | $106.9M | ||
| Q1 24 | $-31.7M | $106.1M |
总资产CTMXNOTE
| Q4 25 | — | $255.1M | ||
| Q3 25 | — | $273.9M | ||
| Q2 25 | $175.1M | $288.3M | ||
| Q1 25 | $98.5M | $299.7M | ||
| Q4 24 | $120.5M | $326.2M | ||
| Q3 24 | $139.0M | $337.9M | ||
| Q2 24 | $159.2M | $346.3M | ||
| Q1 24 | $184.7M | $357.8M |
负债/权益比CTMXNOTE
| Q4 25 | — | 2.07× | ||
| Q3 25 | — | 1.74× | ||
| Q2 25 | — | 1.23× | ||
| Q1 25 | — | 1.20× | ||
| Q4 24 | — | 1.50× | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 1.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $-279.0K |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | $-1.9M |
| 自由现金流率自由现金流/营收 | -84.6% | -8.7% |
| 资本支出强度资本支出/营收 | 0.1% | 7.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-77.7M | $-18.6M |
8季度趋势，按日历期对齐
经营现金流CTMXNOTE
| Q4 25 | — | $-279.0K | ||
| Q3 25 | — | $-8.3M | ||
| Q2 25 | $-15.8M | $-6.2M | ||
| Q1 25 | $-21.0M | $3.3M | ||
| Q4 24 | $-19.9M | $-1.3M | ||
| Q3 24 | $-20.7M | $-3.0M | ||
| Q2 24 | $-19.5M | $-3.7M | ||
| Q1 24 | $-26.0M | $2.7M |
自由现金流CTMXNOTE
| Q4 25 | — | $-1.9M | ||
| Q3 25 | — | $-10.4M | ||
| Q2 25 | $-15.8M | $-7.7M | ||
| Q1 25 | $-21.2M | $1.3M | ||
| Q4 24 | $-20.0M | $-3.4M | ||
| Q3 24 | $-20.7M | $-5.4M | ||
| Q2 24 | $-19.6M | $-6.5M | ||
| Q1 24 | $-26.2M | $1.0M |
自由现金流率CTMXNOTE
| Q4 25 | — | -8.7% | ||
| Q3 25 | — | -46.2% | ||
| Q2 25 | -84.6% | -33.0% | ||
| Q1 25 | -41.6% | 4.7% | ||
| Q4 24 | -52.5% | -11.4% | ||
| Q3 24 | -62.1% | -18.4% | ||
| Q2 24 | -78.2% | -22.1% | ||
| Q1 24 | -63.1% | 3.3% |
资本支出强度CTMXNOTE
| Q4 25 | — | 7.4% | ||
| Q3 25 | — | 9.3% | ||
| Q2 25 | 0.1% | 6.4% | ||
| Q1 25 | 0.2% | 7.2% | ||
| Q4 24 | 0.2% | 6.8% | ||
| Q3 24 | 0.1% | 8.3% | ||
| Q2 24 | 0.4% | 9.4% | ||
| Q1 24 | 0.3% | 5.3% |
现金转化率CTMXNOTE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | 0.05× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
NOTE
| Subscription | $21.2M | 95% |
| Advisory Advertising And Other | $1.0M | 5% |
